Intro

This chapter delves into the specifics of the serotonin-norepinephrine reuptake inhibitors, monasopran (Civella) and levomonasopran (Fetzema), focusing on their unique properties and the financial impact on patients. It discusses their pricing compared to other SNRIs and highlights Civella's distinctive noradrenergic to serotonergic ratio.